Results 41 to 50 of about 919 (164)
Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment
Indian Journal of Ophthalmology, 2016 Based on the indications, one-third to one-half of patients can achieve full-thickness macular hole (FTMH) closure with or without the separation of vitreomacular adhesion (VMA) within 28 days of ocriplasmin treatment. The authors report the case of a 63-
I-Chia Liang +3 more
doaj +1 more source
Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment [PDF]
, 2016 Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical properties following intravitreal ocriplasmin injection for vitreomacular traction. Methods: This is an interventional comparative
Vielmuth, Franziska +7 more
core +1 more source
Applied Sciences, 2020 Methods: Our research was scheduled in Southern Taiwan between April 2017 and December 2017. A total of 280 patients presenting 280 eyes were enrolled and received a series of ocular examinations.
Masaru Takeuchi +2 more
doaj +1 more source
Initial experience with ocriplasmin in the treatment of vitreomacular traction [PDF]
, 2016 This study aimed to report the clinical and structural outcomes of intravitreal ocriplasmin in the treatment of vitreomacular interface disorders in two tertiary centers in Brazil.
José Maurício Botto de Barros Garcia (5760611) +2 more
core +1 more source
BMC Ophthalmology, 2019 Background To investigate, using optical coherence tomography angiography (OCT-A), changes in perfusion density and in the foveal avascular zone (FAZ) in eyes with idiopathic vitreomacular traction (VMT) after ocriplasmin injection. Methods In this pilot
Lorenzo Iuliano +6 more
doaj +1 more source
Ocriplasmin use in a selected case with preserved visual acuity [PDF]
, 2015 Background: Previous studies described cases of Ocriplasmin injections in patients with vitreo-macular traction and reduced central visual acuity. We describe the first case of a patient with 20/20 visual acuity and vitreo-macular traction treated with ...
Francesca Simonelli +12 more
core +2 more sources
Wirkungen und Nebenwirkungen von Ocriplasmin – ein Update
, 2017 ZusammenfassungDie pharmakologische Vitreolyse mit Ocriplasmin ist eine effektive, nicht operative Therapieoption zur Behandlung der vitreomakulären Traktion (VMT) ≤ 1500 µm einschließlich assoziiertem Makulaforamen mit einem Durchmesser von ≤ 400 µm ...
Ricarda Gisela Schumann +2 more
core +1 more source
Acute Ocriplasmin Retinopathy [PDF]
Retina, 2015 Ocriplasmin, a recombinant truncated form of the enzyme plasmin, was approved by the Food and Drug Administration in October 2012 as a first-in-class drug for the nonsurgical treatment of vitreomacular traction (VMT).1 The potential advantages of pharmacologic vitreolysis over surgical vitrectomy include the induction of a “clean” and complete PVD ...
Mark W, Johnson +2 more
openaire +2 more sources
Aging Cell, Volume 25, Issue 4, April 2026.A 14‐protein extracellular matrix aging clock derived from circulating matrisome proteins predicts chronological and biological age across cohorts and biofluids, distinguishes health from disease, and is modulated by rejuvenation interventions in mice, enabling the nomination of potential ECM targets for drug discovery to promote healthy aging ...
Loet Coenen +4 more
wiley +1 more source
Absence of Posterior Vitreous Detachment Is a Risk Factor of Severe Bleb‐Related Endophthalmitis
Journal of Ophthalmology, Volume 2019, Issue 1, 2019., 2019 Purpose. Bleb‐related endophthalmitis (BRE) after glaucoma surgery is an infection caused by bacteria in the avascular bleb gaining access into the eye. We report the clinical features and outcome of 10 consecutive eyes with severe BRE treated at our hospital. Methods.
Kazuhiko Umazume +6 more
wiley +1 more source